Part 2 is an overview of impact of manufacturing, causes of shortages and PBM’s role in drug prices and shortages. In Part 1 (1) of the blog I have suggested that there are opportunities if regulators facilitate the processes. In this part, I am enumerating opportunities that are worth considering and can be exploited. Observations and views are mine and no reflection of any entity or their performance. There is no financial relationship with any company.